SEER icon

Seer Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
GlobeNewsWire
7 days ago
Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L.
Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group
Neutral
Business Wire
8 days ago
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today submitted the following non-binding proposal to acquire the Company for $2.25 per share in cash plus a contingent value right, and also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini for election to the Board of Direct.
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
Neutral
GlobeNewsWire
12 days ago
Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples
REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K.
Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples
Neutral
GlobeNewsWire
22 days ago
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite 23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
Neutral
Business Wire
1 month ago
The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to independent directors Meeta Gulyani and Nicolas Roelofs. *** March 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani and Nicolas Roelofs Dear Ms. Gulyani and Mr. Roelofs, As.
The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
Neutral
Seeking Alpha
1 month ago
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets (“NOLs”).
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
Neutral
GlobeNewsWire
1 month ago
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
Neutral
Business Wire
1 month ago
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** February 23, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: The Board of Directors Members of the Board of Directors (the “Board”).
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
Neutral
GlobeNewsWire
2 months ago
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026